利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.01 秒)

    FCYRIIB-SPECIFIC FC REGION VARIANT
    3.
    发明公开
    FCYRIIB-SPECIFIC FC REGION VARIANT 审中-公开
    FCYRIIB-SPEZIFISCHE FC-REGIONSVARIANTE

    公开(公告)号：EP2889377A4

    公开(公告)日：2016-08-03

    申请号：EP13831250

    申请日：2013-08-23

    申请人： CHUGAI PHARMACEUTICAL CO LTD

    发明人： KATADA HITOSHI ,  KADONO SHOJIRO ,  MIMOTO FUTA ,  IGAWA TOMOYUKI

    IPC分类号： A61K39/00 ,  C07K16/00 ,  C07K16/28 ,  C07K16/30

    CPC分类号： C07K16/00 ,  A61K9/0019 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2866 ,  C07K16/303 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/53 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30

    摘要： An objective of the present invention is to provide an Fc region variant with enhanced Fc³RIIb-binding activity, and/or enhanced binding selectivity to Fc³RIIb compared to Fc³RIIa (type R), as compared to those of a polypeptide containing an Fc region to which an amino acid alteration(s) has not been introduced; a polypeptide which includes the Fc region variant; a pharmaceutical composition containing the polypeptide; preventing therapeutic or preventive agent for immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method of enhancing Fc³RIIb-binding activity and also enhancing binding selectivity to Fc³RIIb compared to Fc³RIIa (type R). It was found that a polypeptide containing an antibody Fc region variant that contains an amino acid sequence in which an amino-acid alteration at position 238 (EU numbering) is combined with other specific amino-acid alterations enhances Fc³RIIb-binding activity, and/or enhances binding selectivity to Fc³RIIb compared to Fc³RIIa (type R).

    摘要翻译： 本发明的目的是提供与FcαRIIa（R型）相比具有增强的Fc3RIIb结合活性和/或增强的对Fc3RIIb的结合选择性的Fc区变体，与含有Fc区的多肽相比， 氨基酸改变尚未引入; 包括Fc区变体的多肽; 含有多肽的药物组合物; 预防包括该药物组合物的免疫性炎性疾病的治疗或预防剂; 其制造方法; 以及增强Fc3RIIb结合活性的方法，并且与FcγRIIa（R型）相比，增强与Fc3RIIb的结合选择性。 发现含有含有氨基酸序列的抗体Fc区变体的多肽，其中238位氨基酸改变（EU编号）与其他特异性氨基酸改变组合增强Fc3RIIb结合活性，和/或 与FcγRIIa（R型）相比，增强与Fc3RIIb的结合选择性。

    FC RIIB-SPECIFIC FC ANTIBODY
    6.
    发明公开
    FC RIIB-SPECIFIC FC ANTIBODY 审中-公开
    FC RIIB特异抗体FC

    公开(公告)号：EP2679681A4

    公开(公告)日：2015-01-28

    申请号：EP12749420

    申请日：2012-02-24

    申请人： CHUGAI PHARMACEUTICAL CO LTD

    发明人： MIMOTO FUTA ,  KURAMOCHI TAICHI ,  IGAWA TOMOYUKI ,  KATADA HITOSHI ,  KADONO SHOJIRO

    IPC分类号： C07K16/00 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28

    CPC分类号： C07K16/2866 ,  C07K16/08 ,  C07K16/18 ,  C07K16/303 ,  C07K2317/524 ,  C07K2317/72

    摘要： An objective of the present invention is to provide a polypeptide containing an Fc region having maintained or decreased binding activities towards both allotypes of Fc³RIIa, types H and R, and having enhanced Fc³RIIb-binding activity in comparison with a parent polypeptide; a pharmaceutical composition containing the polypeptide; an agent for treating or preventing immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method for maintaining or decreasing binding activities towards both allotypes of Fc³RIIa and enhancing the Fc³RIIb-binding activity. Specifically, it is found that a polypeptide containing an antibody Fc region that has an alteration of substituting Pro at position 238 (EU numbering) with Asp or Leu at position 328 (EU numbering) with Glu enhances Fc³RIIb-binding activity, and maintains or decreases binding activities towards both allotypes of Fc³RIIa, types H and R. It is also found that a polypeptide containing an antibody Fc region that contains an alteration of substituting Pro at position 238 (EU numbering) with Asp and several other alterations, enhances Fc³RIIb-binding activity, and maintains or decreases binding activities towards both allotypes of Fc³RIIa, types H and R.